Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis
Kenneth L. Clark(GlaxoSmithKline (United Kingdom)), Mark R. Edbrooke(GlaxoSmithKline (United Kingdom)), Katja Sobczak, Sharon F. Jamison, Joel D. Parry(Age UK), Deborah R. Gill(John Radcliffe Hospital), Paul A. Wilson(GlaxoSmithKline (United Kingdom)), Victoria Pickering, Stephanie Jones(University of Oxford), Jill Darton(GlaxoSmithKline (Sweden)), Vasant Jadhav(Alnylam Pharmaceuticals (United States)), Jill Coates(GlaxoSmithKline (Sweden)), Stephen C. Hyde(John Radcliffe Hospital), Kitty Moores(GlaxoSmithKline (United Kingdom)), Walter Strapps, Michael C. Carr(GlaxoSmithKline (Sweden)), Stephen Hughes(GlaxoSmithKline (United Kingdom)), Daren S. Levin(Northeastern University), Pallav A. Bulsara(GlaxoSmithKline (Sweden)), Lee A. Davies(John Radcliffe Hospital), Ruth J. Mayer(Research Triangle Park Foundation), Wolf-Michael Weber, Ian A. Pringle(University of Oxford), Chris Gruenloh(GlaxoSmithKline (Sweden))
Cited by 37
Related Papers
Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype
|PLoS ONE|2012|849
Characterization of the human patatin-like phospholipase family
|Journal of Lipid Research|2006|302
Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates
|Nature Biotechnology|2022|239